BIOCURE TECHNOLOGY INC. (1WH) - Net Assets
Based on the latest financial reports, BIOCURE TECHNOLOGY INC. (1WH) has net assets worth €- EUR as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
BIOCURE TECHNOLOGY INC. - Net Assets Trend (None–None)
This chart illustrates how BIOCURE TECHNOLOGY INC.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BIOCURE TECHNOLOGY INC. (None–None)
The table below shows the annual net assets of BIOCURE TECHNOLOGY INC. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to BIOCURE TECHNOLOGY INC.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
BIOCURE TECHNOLOGY INC. Competitors by Market Cap
The table below lists competitors of BIOCURE TECHNOLOGY INC. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rare Foods Australia Ltd
AU:RFA
|
$962.23K |
|
International Frontier Resources Corporation
V:IFR
|
$964.26K |
|
FINEQIA INTERN. INC. O.N.
F:FNQA
|
$964.99K |
|
Lapidoth-Heletz Limited Partnership
TA:LPHL-L
|
$966.23K |
|
Badger Capital Corp
V:YVR-P
|
$960.01K |
|
Geiger Counter Limited
LSE:GCL
|
$959.21K |
|
Tearlach Resources Ltd
V:TEA
|
$958.10K |
|
LABOCANNA S.A. ZY-10
F:9Y2
|
$956.57K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BIOCURE TECHNOLOGY INC.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares BIOCURE TECHNOLOGY INC.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently BIOCURE TECHNOLOGY INC. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares BIOCURE TECHNOLOGY INC.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $316,397,405
- Average return on equity (ROE) among peers: -814.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BIOCURE TECHNOLOGY INC. (1WH) | €- | N/A | N/A | $960.84K |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $24.67 Million |
| PreveCeutical Medical Inc (18H) | $-6.64 Million | 0.00% | 0.00x | $3.34 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $978.02 Million |
| ONCOARENDI THERAP ZY-01 (1B1) | $100.93 Million | -28.11% | 0.11x | $24.94 Million |
| Flerie AB (publ) (1NP1) | $4.20 Billion | -5.43% | 0.01x | $231.62 Million |
| NUFORMIX PLC LS -001 (1RT) | $5.69 Million | -22.04% | 0.06x | $1.53 Million |
| 1S90 (1S90) | $13.78 Million | 0.99% | 9.14x | $70.17 Million |
| Strategic Partners A/S (1TB0) | $9.34 Million | -6708.84% | 17.55x | $3.69 Million |
| Entheon Biomedical Corp. (1XU) | $614.57K | -1386.45% | 0.25x | $502.28K |
| 25K0 (25K0) | $-186.02 Million | 0.00% | 0.00x | $125.12 Million |
About BIOCURE TECHNOLOGY INC.
Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab for age-related vision loss; and Filgrastim for chemotherapy effects treatments. It also engages in the research and development of CAR T … Read more